Supplementary Files
Keywords
Asthma
Mites
Allergen
Blomia
Dermatophagoides
Efficacy
Cost
Economy
Immunotherapy
Sensitization
Abstract
Background: Immunotherapy has proven to be effective in controlling allergic asthma. However, few studies have evaluated whether the control and reduction of drug treatment persist after treatment ends.
Objective: To evaluate the effect of immunotherapy with mites in asthma patients after two years of its suspension on drug treatment and number of exacerbations.
Material and method: Observational study ambispective with active group (immunotherapy and pharmacotherapy) and control (only pharmacotherapy) group followed up for 5 years divided into two phases: 3 years of application of immunotherapy and two year of follow-up after its suspension.
Results: 122 patients in the active group and 384 in the control group were included. Both groups had fewer exacerbations after the sixth month (p = 0.04). After nine months the active group had a significant reduction in the use of inhaled steroids (p = 0.05) compared to the control group. Two years after finished immunotherapy, patients in the active group received a lower inhaler doses than the control group. Children under 14 years mono-sensitized had the best response in all parameters evaluated.
Conclusion: The allergen immunotherapy improves asthma control and reduces the required doses of pharmacotherapy. These effects have an important impact on quality of life and perhaps economically for patients with asthma. The beginning at an early age seems to have a major impact.
References
Dennis R, Caraballo L, Garcia E, Caballero A, Aristizabal G, Cordoba H, et al. Asthma and other allergic conditions in Colombia: a study in 6 cities. Ann Allergy Asthma Immunol. 2004;93(6):568-74.
Vergara C, Caraballo L. Asthma mortality in Columbia. Ann Allergy Asthma Immunol. 1998;80(1):55-60.
Neffen H, Baena-Cagnani CE, Malka S, Sole D, Sepulveda R, Caraballo L, et al. Asthma mortality in Latin America. J Investig Allergol Clin Immunol. 1997;7(4):249-53.
Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. 2006;355(21):2226-35.
Anandan C, Nurmatov U, van Schayck O, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy. 2010;65(2):152-67. 6. Caraballo L, Acevedo N. Allergy in the tropics: the impact of cross-reactivity between mites and ascaris. Front Biosci (Elite Ed). 2011;3:51-64.
Burbach G, Heinzerling L, Edenharter G, Bachert C, Bindslev-Jensen C, Bonini S, et al. GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy. 2009;64(10):1507-15.
Sánchez J, Diez S, Cardona R. [Frequency of sensitization to animals in a tropical area]. Rev Alerg Mex. 2014;61(2):81-9. 9. Sanchez J, Diez S, Cardona R. Sensibilización a aeroalergenos en pacientes alérgicos de Medellín, Colombia Revista Alergia México. 2012;59(3):139-47.
Fasce L, Tosca MA, Baroffio M, Olcese R, Ciprandi G. Atopy in wheezing infants always starts with monosensitization. Allergy Asthma Proc. 2007;28(4):449-53.
Alzakar RH, Alsamarai AM. Efficacy of immunotherapy for treatment of allergic asthma in children. Allergy Asthma Proc. 2010;31(4):324-30.
Cox L. Allergen immunotherapy and asthma: efficacy, safety, and other considerations. Allergy Asthma Proc. 2008;29(6):580-9.
Cady C, Powell M, Harbeck R, Giclas P, Murphy J, Katial R, et al. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunol Lett. 2010;130(1-2):57-65.
Wing K, Sakaguchi S. Regulatory T cells as potential immunotherapy in allergy. Curr Opin Allergy Clin Immunol. 2006;6(6):482-8. 15. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122(5):951-60.
Copenhaver CC, Parker A, Patch S. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice. Ann Allergy Asthma Immunol. 2011;107(5):441-7.
Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599-609.
Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64(11):1570-9.
Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010(8):CD001186.
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10- year follow-up on the PAT study. Allergy. 2007;62(8):943-8.
Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251-6
Sánchez J, Restrepo M, Diez S, Cardona R. Comparación del efecto clínico de la inmunoterapia en pacientes con asma alérgica según la edad y el patrón de sensibilización. Alergia, Asma e Inmunología Pediátricas. 2014;23(1):6-14.
Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-62
Heinzerling LM, Burbach GJ, Edenharter G, Bachert C, Bindslev-Jensen C, Bonini S, et al. GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy. 2009;64(10):1498-506.
Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010;126(5):942-9.
Kwon YS, Oh SH, Wu WH, Bae BG, Lee HJ, Lee MG, et al. CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy. Exp Dermatol. 2010;19(3):246-51.
Rossi RE, Monasterolo G, Incorvaia C, Moingeon P, Frati F, Passalacqua G, et al. Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy. Clin Mol Allergy. 2010;8:4.
Cantillo JF, Puerta L. [New approaches for allergen-specific immunotherapy]. Biomedica. 2010;30(3):440-53.
Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy. 2012;67(9):1087-105.
Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technology Assessment. 2013;17(27).
Bruggenjurgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. 2008;101(3):316-24.
Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2013;131(4):1084-91.
Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014;14(4):363-70.
Reinhold T, Ostermann J, Thum-Oltmer S, Bruggenjurgen B. Influence of subcutaneous specific immunotherapy on drug costs in children suffering from allergic asthma. Clinical and translational allergy. 2013;3(1):30.
Chen J, Xiang J, Wang Y, Shi Q, Tan H, Kong W. [Health economics analysis of specific immunotherapy in allergic rhinitis accompanied with asthma]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery. 2013;27(17):925-8.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2016 Revista Alergia México